Effect of L-carnitine supplementation on lipid profile and apolipoproteins in children on hemodialysis: a randomized placebo-controlled clinical trial.
Apolipoproteins
Carnitine
Hemodialysis
Lipids
Pediatrics
Stage 5 chronic kidney disease
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
11
01
2021
accepted:
02
04
2021
revised:
26
02
2021
pubmed:
27
5
2021
medline:
26
3
2022
entrez:
26
5
2021
Statut:
ppublish
Résumé
Cardiovascular disease (CVD) is the leading cause of death in children with chronic kidney disease (CKD) and accounts for 40% of all deaths among pediatric patients with stage 5 chronic kidney disease (CKD 5). Dyslipidemia is common in children with CKD and is considered one of the major causes of CVD in these patients. As carnitine plays a key role in lipid metabolism and because plasma levels are reduced in hemodialysis patients, the aim of this study was to determine the effects of L-carnitine supplementation on serum lipid profiles, apolipoproteins, and free carnitine (FC) levels. A total of 30 children on hemodialysis (6-18 years) were enrolled and 24 completed the study. Twelve patients received 50 mg/kg/day L-carnitine, while the other 12 patients received placebo for 10 weeks. Serum FC, total cholesterol (TC), LDL-C, HDL-C, TG, Apolipoprotein B (ApoB), and Apolipoprotein A1 (ApoA1) were determined at the baseline and after the intervention. One-way repeated measures analysis was used to evaluate the effects of L-carnitine supplementation. Oral L-carnitine supplementation led to decreased ApoB levels and ApoB/ApoA1 ratio, but these changes were not significant compared to placebo. Meanwhile, L-carnitine supplementation significantly reduced serum LDL-C and TC and increased serum FC compared to placebo. No significant changes were observed in serum TG and HDL-C levels. Given the significant reduction in LDL-C and TC levels, L-carnitine supplementation had positive effects on improving hyperlipidemia in children receiving hemodialysis. For more decisive results, studies with longer duration of L-carnitine therapy on children receiving hemodialysis with significant dyslipidemia are recommended. We registered the present trial in the Iranian Registry of Clinical Trials website (available at: http://www.irct.ir , identifier: IRCT20170202032367N2).
Sections du résumé
BACKGROUND
Cardiovascular disease (CVD) is the leading cause of death in children with chronic kidney disease (CKD) and accounts for 40% of all deaths among pediatric patients with stage 5 chronic kidney disease (CKD 5). Dyslipidemia is common in children with CKD and is considered one of the major causes of CVD in these patients. As carnitine plays a key role in lipid metabolism and because plasma levels are reduced in hemodialysis patients, the aim of this study was to determine the effects of L-carnitine supplementation on serum lipid profiles, apolipoproteins, and free carnitine (FC) levels.
METHODS
A total of 30 children on hemodialysis (6-18 years) were enrolled and 24 completed the study. Twelve patients received 50 mg/kg/day L-carnitine, while the other 12 patients received placebo for 10 weeks. Serum FC, total cholesterol (TC), LDL-C, HDL-C, TG, Apolipoprotein B (ApoB), and Apolipoprotein A1 (ApoA1) were determined at the baseline and after the intervention. One-way repeated measures analysis was used to evaluate the effects of L-carnitine supplementation.
RESULTS
Oral L-carnitine supplementation led to decreased ApoB levels and ApoB/ApoA1 ratio, but these changes were not significant compared to placebo. Meanwhile, L-carnitine supplementation significantly reduced serum LDL-C and TC and increased serum FC compared to placebo. No significant changes were observed in serum TG and HDL-C levels.
CONCLUSION
Given the significant reduction in LDL-C and TC levels, L-carnitine supplementation had positive effects on improving hyperlipidemia in children receiving hemodialysis. For more decisive results, studies with longer duration of L-carnitine therapy on children receiving hemodialysis with significant dyslipidemia are recommended.
TRIAL REGISTRATION
We registered the present trial in the Iranian Registry of Clinical Trials website (available at: http://www.irct.ir , identifier: IRCT20170202032367N2).
Identifiants
pubmed: 34037885
doi: 10.1007/s00467-021-05080-1
pii: 10.1007/s00467-021-05080-1
doi:
Substances chimiques
Apolipoproteins
0
Lipids
0
Carnitine
S7UI8SM58A
Banques de données
IRCT
['20170202032367N2']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
3741-3747Informations de copyright
© 2021. IPNA.
Références
Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA et al (2014) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 63:713–735. https://doi.org/10.1053/j.ajkd.2014.01.416
doi: 10.1053/j.ajkd.2014.01.416
pubmed: 24647050
Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS et al (2016) Global prevalence of chronic kidney disease–a systematic review and meta-analysis. PLoS One 11:e0158765
doi: 10.1371/journal.pone.0158765
Harambat J, Van Stralen KJ, Kim JJ, Tizard EJ (2012) Epidemiology of chronic kidney disease in children. Pediatr Nephrol 27:363–373 Erratum in 27:507
doi: 10.1007/s00467-011-1939-1
Becherucci F, Roperto RM, Materassi M, Romagnani P (2016) Chronic kidney disease in children. Clin Kidney J 9:583–591. https://doi.org/10.1093/ckj/sfw047
doi: 10.1093/ckj/sfw047
pubmed: 27478602
pmcid: 4957724
Lilien MR, Groothoff JW (2009) Cardiovascular disease in children with CKD or ESRD. Nat Rev Nephrol 5:229
doi: 10.1038/nrneph.2009.10
Wong CJ, Moxey-Mims M, Jerry-Fluker J, Warady BA, Furth SL (2012) CKiD (CKD in children) prospective cohort study: a review of current findings. Am J Kidney Dis 60:1002–1011. https://doi.org/10.1053/j.ajkd.2012.07.018
doi: 10.1053/j.ajkd.2012.07.018
pubmed: 23022429
pmcid: 3496011
Khurana M, Silverstein DM (2015) Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease. Pediatr Nephrol 30:2073–2084
doi: 10.1007/s00467-015-3075-9
Longo N, Frigeni M, Pasquali M (2016) Carnitine transport and fatty acid oxidation. Biochim Biophys Acta 1863:2422–2435. https://doi.org/10.1016/j.bbamcr.2016.01.023
doi: 10.1016/j.bbamcr.2016.01.023
pubmed: 26828774
pmcid: 4967041
Tu J, Cheung WW, Mak RH (2016) Inflammation and nutrition in children with chronic kidney disease. World J Nephrol 5:274. https://doi.org/10.5527/wjn.v5.i3.274
doi: 10.5527/wjn.v5.i3.274
pubmed: 27152263
pmcid: 4848150
Verrina E, Caruso U, Calevo MG, Emma F, Sorino P, De Palo T et al (2007) Effect of carnitine supplementation on lipid profile and anemia in children on chronic dialysis. Pediatr Nephrol 22:727–733
doi: 10.1007/s00467-006-0408-8
Hedayati SS (2006) Dialysis-related carnitine disorder. Semin Dial 19:323–328
doi: 10.1111/j.1525-139X.2006.00180.x
El-Metwally TH, Hamed EA, Ahmad AR, Mohamed NA (2003) Dyslipidemia, oxidative stress and cardiac dysfunction in children with chronic renal failure: effects of L-carnitine supplementation. Ann Saudi Med 23:270–277
doi: 10.5144/0256-4947.2003.270
Koşan C, Sever L, Arısoy N, Çalışkan S, Kasapçopur Ö (2003) Carnitine supplementation improves apolipoprotein B levels in pediatric peritoneal dialysis patients. Pediatr Nephrol 18:1184–1188
doi: 10.1007/s00467-003-1302-2
Warady BA, Borum P, Stall C, Millspaugh J, Taggart E, Lum G (1990) Carnitine status of pediatric patients on continuous ambulatory peritoneal dialysis. Am J Nephrol 10:109–114. https://doi.org/10.1159/000168064
doi: 10.1159/000168064
pubmed: 2349954
Shakeri A, Tabibi H, Hedayati M (2010) Effects of l-carnitine supplement on serum inflammatory cytokines, C-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with Lp (a) hyperlipoproteinemia. Hemodial Int 14:498–504. https://doi.org/10.1111/j.1542-4758.2010.00476.x
doi: 10.1111/j.1542-4758.2010.00476.x
pubmed: 20812958
Mir S, Kantar M, Yalaz M, Keskinoglu A, Coker IS, Huseyinov A (2002) Effect of hemodialysis on carnitine levels in children with chronic renal failure. Pediatr Int 44:70–73. https://doi.org/10.1046/j.1442-200X.2002.01498.x
doi: 10.1046/j.1442-200X.2002.01498.x
pubmed: 11982875
Topaloğlu R, Celiker A, Saatçi U, Kilinç K, Bakkaloğlu A, Beşbaş N, Sezaözen TK (1998) Effect of carnitine supplementation on cardiac function in hemodialyzed children. Pediatr Int 40:26–29. https://doi.org/10.1111/j.1442-200X.1998.tb01397.x
doi: 10.1111/j.1442-200X.1998.tb01397.x
Steiber AL, Davis AT, Spry L, Strong J, Buss ML, Ratkiewicz MM et al (2006) Carnitine treatment improved quality-of-life measure in a sample of Midwestern hemodialysis patients. J Parenter Enter Nutr 30:10–15. https://doi.org/10.1177/014860710603000110
doi: 10.1177/014860710603000110
Patel HP (2010) Early origins of cardiovascular disease in pediatric chronic kidney disease. Ren Fail 32:1–9
doi: 10.3109/08860220903288534
Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A et al (2002) Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 13:1918–1927. https://doi.org/10.1097/01.ASN.0000019641.41496.1E
doi: 10.1097/01.ASN.0000019641.41496.1E
pubmed: 12089389
Saland JM, Pierce CB, Mitsnefes MM, Flynn JT, Goebel J, Kupferman JC et al (2010) Dyslipidemia in children with chronic kidney disease. Kidney Int 78:1154–1163. https://doi.org/10.1038/ki.2010.311
doi: 10.1038/ki.2010.311
pubmed: 20736985
pmcid: 3222564
Vaziri ND, Deng G, Liang K (1999) Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant 14:1462–1466. https://doi.org/10.1093/ndt/14.6.1462
doi: 10.1093/ndt/14.6.1462
pubmed: 10383008
Vaziri ND, Moradi H (2006) Mechanisms of dyslipidemia of chronic renal failure. Hemodial Int 10:1–7. https://doi.org/10.1111/j.1542-4758.2006.01168.x
doi: 10.1111/j.1542-4758.2006.01168.x
pubmed: 16441821
Feng Y, Guo C, Wei J, Yang J, Ge Y, Gao L (2001) Necessity of carnitine supplementation in semistarved rats fed a high-fat diet. Nutrition 17:628–631. https://doi.org/10.1016/S0899-9007(01)00601-3
doi: 10.1016/S0899-9007(01)00601-3
pubmed: 11448585
Tanaka Y, Sasaki R, Fukui F, Waki H, Kawabata T, Okazaki M et al (2004) Acetyl-L-carnitine supplementation restores decreased tissue carnitine levels and impaired lipid metabolism in aged rats. J Lipid Res 45:729–735. https://doi.org/10.1194/jlr.M300425-JLR200
doi: 10.1194/jlr.M300425-JLR200
pubmed: 14703509
Zarny L, Bernstein L (1995) Serum cholesterol: an indicator of malnutrition. J Am Diet Assoc 95:A25. https://doi.org/10.1016/S0002-8223(95)00436-X
doi: 10.1016/S0002-8223(95)00436-X
Sato Y, Fujimoto S, Toida T, Nakagawa H, Yamashita Y, Iwakiri T et al (2016) Apoprotein B/apoprotein A-1 ratio and mortality among prevalent dialysis patients. Clin J Am Soc Nephrol 11:840–846. https://doi.org/10.2215/CJN.09830915
doi: 10.2215/CJN.09830915
pubmed: 26912548
pmcid: 4858486
Kirmizis D, Koutoupa E, Tsiandoulas A, Valtopoulou A, Niavis G, Markou P, Barboutis K (2007) Serum lipid profile constituents as markers of cardiovascular morbidity in patients on chronic hemodialysis. Biomark Insights 1:185–192
pubmed: 19690648
pmcid: 2716782
Diaz M, Lopez F, Hernandez F, Urbina JA (2000) l-Carnitine effects on chemical composition of plasma lipoproteins of rabbits fed with normal and high cholesterol diets. Lipids 35:627–632. https://doi.org/10.1007/s11745-000-0566-2
doi: 10.1007/s11745-000-0566-2
pubmed: 10901424